AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced it will be a sponsor of the Achroma Corp program, No Roadblocks.
AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.
Gene Therapy Manufacturer Expands Its Footprint in Alachua County
AGTC, a UF startup and UF Innovate | Sid Martin Biotech alum, is determined to change the rare diseases narrative.
AGTC Breaks Ground on New Biotech Lab in Alachua
Applied Genetic Technologies Corporation will build a new 21,000 square foot laboratory facility in Alachua. The facility will include control labs and a manufacturing suite and will add 50 jobs.
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has initiated plans to lease a build-to-suit 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility adjacent to its Florida facility to prepare for anticipated late-stage development of its X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM) programs.
AGTC Licenses Promoter Technology to SparingVision SAS
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced a licensing agreement that provides its proprietary cone-specific promoter technology to SparingVision SAS, a genomic medicine company developing vision-saving treatments for ocular diseases.
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
AGTC will provide TeamedOn with the clinical trial material, pre-clinical and clinical data generated for the development of AGTC’s investigational intravitreal gene therapy candidate, rAAV2tYF-CB-hRS1
Manipulating Milestones in Pandemic Times with AGTC’s Sue Washer
The COVID-19 pandemic continues to disrupt biopharma clinical trials, especially those conducted with at-risk patient populations. From patient recruitment to data collection, clinical trials execution became considerably more challenging in 2020. On this episode of The Business Of Biotech, UF startup and UF Innovate | Sid Martin Biotech graduate AGTC CEO Sue Washer gives us a behind-the-scenes look at the creative measures her company took to serve a geographically dispersed clinical patient population and ensure her company met clinical milestones.
AGTC Goes Mobile to Avoid Clinical Trial Chaos
When leaders of UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC realized how disruptive COVID-19 might become, they developed a plan—several of them, in fact—to minimize clinical chaos.
AGTC Reports Additional Positive Data From Its Phase 1/2 Clinical Trial in Patients With X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
